You have free access to this content

Cancer

Cover image for Vol. 119 Issue 4

15 February 2013

Volume 119, Issue 4

Pages 701–924

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Original Articles
    4. Errata
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
  2. Original Articles

    1. Top of page
    2. CancerScope
    3. Original Articles
    4. Errata
    1. Disease Site

      Breast Disease
      You have free access to this content
      Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer (pages 704–713)

      Hiroji Iwata, Norikazu Masuda, Yasuaki Sagara, Takayuki Kinoshita, Seigo Nakamura, Yasuhiro Yanagita, Reiki Nishimura, Hirotaka Iwase, Shunji Kamigaki, Hiroyuki Takei, Hitoshi Tsuda, Nobuya Hayashi and Shinzaburo Noguchi

      Article first published online: 12 SEP 2012 | DOI: 10.1002/cncr.27818

      The authors assess correlations between the expression of Ki-67 nuclear antigen Ki-67; tumor and histopathologic responses, and hormone receptor status in premenopausal patients with early stage breast cancer who receive either anastrozole plus goserelin or tamoxifen plus goserelin before undergoing surgery. The best overall tumor response is better with anastrozole compared with tamoxifen among patients who have baseline Ki-67 index scores of either ≥20% or <20%.

    2. Gastrointestinal Disease
      You have free access to this content
      KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer : A systematic review and meta-analysis (pages 714–721)

      Chen Mao, Ya-Fang Huang, Zu-Yao Yang, Da-Yong Zheng, Jin-Zhang Chen and Jin-Ling Tang

      Article first published online: 12 SEP 2012 | DOI: 10.1002/cncr.27804

      Patients with metastatic colorectal cancer who have the v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) p.G13D mutation (an amino acid substitution at position 13 in KRAS from a glycine to an aspartic acid) appear to benefit more from cetuximab than patients who have KRAS codon 12 mutations. Whether or not patients with metastatic colorectal cancer who have the p.G13D mutation should be excluded from cetuximab treatment needs to be reconsidered.

    3. You have free access to this content
      A population-based study of metastatic colorectal cancer in individuals aged ≥80 years : Findings from the South Australian Clinical Registry for Metastatic Colorectal Cancer (pages 722–728)

      Rajiv Kumar, Kunal Jain, Carol Beeke, Timothy J. Price, Amanda R. Townsend, Rob Padbury, David Roder, Graeme P. Young, Alison Richards and Christos S. Karapetis

      Article first published online: 18 SEP 2012 | DOI: 10.1002/cncr.27802

      Patients with metastatic colorectal cancer (mCRC) aged ≥80 years are less likely to receive intervention for their mCRC and have poorer survival. Survival for selected patients aged ≥80 years, who received chemotherapy, was similar to survival for those patients younger than 80 years, despite receiving single-agent therapy.

    4. You have free access to this content
      CD66c is a novel marker for colorectal cancer stem cell isolation, and its silencing halts tumor growth in vivo (pages 729–738)

      Marica Gemei, Peppino Mirabelli, Rosa Di Noto, Claudia Corbo, Antonino Iaccarino, Anna Zamboli, Giancarlo Troncone, Gennaro Galizia, Eva Lieto, Luigi Del Vecchio and Francesco Salvatore

      Article first published online: 1 OCT 2012 | DOI: 10.1002/cncr.27794

      Cluster of differentiation 66c (CD66c) (also known as carcinoembryonic antigen-related cell adhesion molecule 6) is specifically expressed by colorectal cancer stem cells compared with normal colon stem cells. This new marker has several functional implications in tumor growth and progression.

    5. You have free access to this content
      Elderly patients with colon cancer have unique tumor characteristics and poor survival (pages 739–747)

      Supriya S. Patel, Rebecca Nelson, Julian Sanchez, Wendy Lee, Lori Uyeno, Julio Garcia-Aguilar, Arti Hurria and Joseph Kim

      Article first published online: 25 SEP 2012 | DOI: 10.1002/cncr.27753

      Older patients with colon cancer have distinct clinical and disease characteristics, as well as decreased survival. These age-related disparities highlight the need to understand differences in management and subsequent outcomes for treating colon cancer in aging patients.

    6. You have free access to this content
      Prognostic factors for recurrence and survival in anal cancer : Generating hypotheses from the mature outcomes of the first United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial (ACT I) (pages 748–755)

      Robert Glynne-Jones, David Sebag-Montefiore, Richard Adams, Simon Gollins, Mark Harrison, Helen M. Meadows, Mark Jitlal and for the United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial Working Party

      Article first published online: 25 SEP 2012 | DOI: 10.1002/cncr.27825

      This analysis of the first United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial (ACT I) complements 2 other studies, adding further evidence that palpable inguinal lymph node status and sex are independently prognostic of overall survival, locoregional failure, and anal cancer death. In addition, after adjusting for sex and lymph node status, presenting hemoglobin level is identified as another prognostic factor for anal cancer death.

    7. Genitourinary Disease
      You have free access to this content
      Combination of molecular alterations and smoking intensity predicts bladder cancer outcome : A report from the Los Angeles Cancer Surveillance Program (pages 756–765)

      Anirban P. Mitra, Jose E. Castelao, Debra Hawes, Denice D. Tsao-Wei, Xuejuan Jiang, Shan-Rong Shi, Ram H. Datar, Eila C. Skinner, John P. Stein, Susan Groshen, Mimi C. Yu, Ronald K. Ross, Donald G. Skinner, Victoria K. Cortessis and Richard J. Cote

      Article first published online: 14 JAN 2013 | DOI: 10.1002/cncr.27763

      Combined analysis of molecular alterations in the apoptosis, cell cycle regulation, inflammation, angiogenesis, and invasion pathways is prognostic in bladder cancer. When used in addition to information derived from a patient's smoking history, the value of these biomarkers in predicting outcome is significantly higher than that of routine clinicopathological parameters alone.

    8. Head and Neck Disease
      You have free access to this content
      A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck (pages 766–773)

      Douglas Adkins, Jessica Ley, Kathryn Trinkaus, Wade Thorstad, James Lewis Jr, Tanya Wildes, Barry A. Siegel, Farrokh Dehdashti, Hiram Gay, Paul Mehan and Brian Nussenbaum

      Article first published online: 18 SEP 2012 | DOI: 10.1002/cncr.27741

      Induction chemotherapy with nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil resulted in a high complete response rate (53%) at the primary tumor site, even in large tumors, and did not adversely affect delivery of definitive chemoradiation. Two-year survival outcomes with this regimen were very favorable.

    9. You have free access to this content
      Chrysin activates Notch1 signaling and suppresses tumor growth of anaplastic thyroid carcinoma in vitro and in vivo (pages 774–781)

      Xiao-Min Yu, TramAnh Phan, Priyesh N. Patel, Renata Jaskula-Sztul and Herbert Chen

      Article first published online: 18 SEP 2012 | DOI: 10.1002/cncr.27742

      The extremely poor prognosis of anaplastic thyroid carcinoma reflects the lack of curative therapeutic strategies. This report suggests chrysin as a potential therapy, which activates Notch1 signaling and suppresses anaplastic thyroid carcinoma tumor growth both in vitro and in vivo via apoptosis.

    10. Hematologic Malignancies
      You have free access to this content
      Toll-like receptor-4 signaling in mantle cell lymphoma : Effects on tumor growth and immune evasion (pages 782–791)

      Lijuan Wang, Yi Zhao, Jianfei Qian, Luhong Sun, Yong Lu, Haiyan Li, Yi Li, Jing Yang, Zhen Cai and Qing Yi

      Article first published online: 22 AUG 2012 | DOI: 10.1002/cncr.27792

      The results from this study indicate that Toll-like receptor-4 (TLR4) signaling triggers a cascade that leads to mantle cell lymphoma growth and evasion of immune surveillance. Thus, TLR4 signaling molecules may be novel therapeutic targets in patients with mantle cell lymphoma.

    11. Chest and Lung Disease
      You have free access to this content
      Methylation of breast cancer susceptibility gene 1 (BRCA1) predicts recurrence in patients with curatively resected stage I non–small cell lung cancer (pages 792–798)

      Hiroaki Harada, Kazuaki Miyamoto, Yoshinori Yamashita, Kikuo Nakano, Kiyomi Taniyama, Yoshihiro Miyata, Hideki Ohdan and Morihito Okada

      Article first published online: 18 JAN 2013 | DOI: 10.1002/cncr.27754

      Molecular biomarkers that can accurately predict prognosis need to be identified to improve clinical outcomes. Methylated BRCA1 (breast cancer susceptibility gene 1) is a potential biomarker that predicts the outcome of disease after curative resection of stage I non–small cell lung cancer.

    12. Melanoma
      You have free access to this content
      Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma (pages 799–805)

      Sapna P. Patel, Alexander J. Lazar, Nicholas E. Papadopoulos, Ping Liu, Jeffrey R. Infante, Michelle R. Glass, Carol S. Vaughn, Patricia M. LoRusso, Roger B. Cohen, Michael A. Davies and Kevin B. Kim

      Article first published online: 12 SEP 2012 | DOI: 10.1002/cncr.27790

      The authors analyze tumor mutation status and response to therapy in patients with melanoma who were enrolled on a phase 1 study of selumetinib-containing regimens. The results demonstrate that patients who have melanoma with a v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutation have a considerably better clinical benefit from selumetinib-containing regimens than those without a BRAF mutation.

    13. Neuro-Oncology
      You have free access to this content
      Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas (pages 806–813)

      Xiao-Wei Wang, Blandine Boisselier, Marta Rossetto, Yannick Marie, Ahmed Idbaih, Karima Mokhtari, Konstantinos Gousias, Khê Hoang-Xuan, Jean-Yves Delattre, Matthias Simon, Marianne Labussière and Marc Sanson

      Article first published online: 26 NOV 2012 | DOI: 10.1002/cncr.27798

      A single-nucleotide polymorphism (SNP) located on codon 105 of the isocitrate dehydrogenase 1 (IDH1) gene (reference SNP rs11554137) is analyzed in 3 independent series of patients with gliomas. The SNP rs11554137 is independent of the occurrence of somatic mutation on IDH1 codon 132, but, per se, has a prognostic impact in malignant gliomas.

    14. You have free access to this content
      Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme (pages 814–824)

      Wei Zhang, Jing Zhang, Wei Yan, Gan You, Zhaoshi Bao, Shouwei Li, Chunsheng Kang, Chuanlu Jiang, Yongping You, Yuxiang Zhang, Clark C. Chen, Sonya Wei Song and Tao Jiang

      Article first published online: 18 SEP 2012 | DOI: 10.1002/cncr.27826

      A 5-microRNA prognostic signature is investigated in patients with glioblastoma and is able to identify patients who have a high risk of an unfavorable clinical outcome. This prognostic signature has the potential to personalize cancer management and should be evaluated in further prospective studies.

    15. Skin
      You have free access to this content
      Hydrochlorothiazide and cutaneous T cell lymphoma : Prospective analysis and case series (pages 825–831)

      Richard R. Jahan-Tigh, Auris O. Huen, Grace L. Lee, Jenny V. Pozadzides, Ping Liu and Madeleine Duvic

      Article first published online: 5 SEP 2012 | DOI: 10.1002/cncr.27740

      Mycosis fungoides and leukemic Sézary syndrome are the most common cutaneous T cell lymphomas, but their etiology remains unknown. After patients were observed with hydrochlorothiazide (HCTZ)-associated cutaneous T cell lymphoma, HCTZ was examined as a putative chronic antigen in a cohort of prospectively staged patients. HCTZ is commonly prescribed and may be a putative antigen in a small subset of early mycosis fungoides patients. Careful drug histories and a trial off medication are warranted.

    16. Discipline

      Clinical Trials
      You have free access to this content
      Pain outcomes in patients with advanced breast cancer and bone metastases : Results from a randomized, double-blind study of denosumab and zoledronic acid (pages 832–838)

      Charles S. Cleeland, Jean-Jacques Body, Alison Stopeck, Roger von Moos, Lesley Fallowfield, Susan D. Mathias, Donald L. Patrick, Mark Clemons, Katia Tonkin, Norikazu Masuda, Allan Lipton, Richard de Boer, Stefania Salvagni, Celia Tosello Oliveira, Yi Qian, Qi Jiang, Roger Dansey, Ada Braun and Karen Chung

      Article first published online: 5 SEP 2012 | DOI: 10.1002/cncr.27789

      Denosumab demonstrates improved pain prevention and comparable pain palliation compared with zoledronic acid. Fewer denosumab-treated patients shift to strong opioid analgesic use.

    17. Disparities Research
      You have free access to this content
      Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network (pages 839–846)

      Rachel A. Freedman, Melissa E. Hughes, Rebecca A. Ottesen, Jane C. Weeks, Yulei He, Yu-Ning Wong, Richard Theriault and Nancy L. Keating

      Article first published online: 25 SEP 2012 | DOI: 10.1002/cncr.27831

      The authors report differences in the rate at which patients complete treatment with trastuzumab according to race and education among women who receive treatment at National Comprehensive Cancer Network centers. Efforts to assure the appropriate use of trastuzumab and to understand treatment barriers are needed and may lead to improved outcomes.

    18. Epidemiology
      You have free access to this content
      Smoking status and survival in the national comprehensive cancer network non–small cell lung cancer cohort (pages 847–853)

      Amy K. Ferketich, Joyce C. Niland, Rizvan Mamet, Carrie Zornosa, Thomas A. D'Amico, David S. Ettinger, Gregory P. Kalemkerian, Katherine M. Pisters, Mary E. Reid and Gregory A. Otterson

      Article first published online: 28 SEP 2012 | DOI: 10.1002/cncr.27824

      Patients who are smoking at the time of diagnosis have worse survival compared with never smokers. Although some of these differences probably are related to tumor biology, to improve survival, it is prudent to encourage all smokers to quit smoking if they are diagnosed with non–small cell lung cancer.

      Corrected by:

      Erratum: Erratum

      Vol. 119, Issue 6, 1290, Article first published online: 26 NOV 2012

    19. Outcomes Research
      You have free access to this content
      Chemotherapy use and patient treatment preferences in advanced colorectal cancer : A prospective cohort study (pages 854–862)

      S. Yousuf Zafar, Jennifer L. Malin, Steven C. Grambow, David H. Abbott, Jane T. Kolimaga, Leah L. Zullig, Jane C. Weeks, John Z. Ayanian, Katherine L. Kahn, Patricia A. Ganz, Paul J. Catalano, Dee W. West, Dawn Provenzale and for the Cancer Care Outcomes Research & Surveillance (CanCORS) Consortium

      Article first published online: 12 SEP 2012 | DOI: 10.1002/cncr.27815

      The authors investigate how patient preferences guide the course of palliative chemotherapy for advanced colorectal cancer. The majority of patients receive such treatment even if they express negative or marginal preferences or beliefs regarding chemotherapy.

    20. You have free access to this content
      Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy (pages 863–870)

      Alicia K. Morgans, Matthew R. Smith, A. James O'Malley and Nancy L. Keating

      Article first published online: 12 OCT 2012 | DOI: 10.1002/cncr.27830

      The current analysis of Surveillance, Epidemiology, and End Results/Medicare data suggests that few prostate cancer survivors who receive long-term androgen-deprivation therapy (ADT) undergo bone density testing; and several key populations, including African Americans and older men, have considerably lower rates of bone density screening.

    21. Pediatric Oncology
      You have free access to this content
      Pediatric sarcoma in Central America : Outcomes, challenges, and plans for improvement (pages 871–879)

      Paola Friedrich, Roberta Ortiz, Kelly Strait, Soad Fuentes, Yéssica Gamboa, Ingrid Arambú, María Ah-Chu-Sanchez, Wendy London, Carlos Rodríguez-Galindo, Federico Antillón-Klussmann, Fulgencio Báez and for the Central American Association of Pediatric Hematologists Oncologists (AHOPCA)

      Article first published online: 12 SEP 2012 | DOI: 10.1002/cncr.27816

      Children with cancer in middle-income countries face a poor prognosis. The high rates of metastases and treatment abandonment and the difficulty with upfront treatment effectiveness are important contributors to the poor survival of children with pediatric sarcomas in Central America.

    22. Quality of Life
      You have free access to this content
      Randomized controlled trial of maintaining quality of life during radiotherapy for advanced cancer (pages 880–887)

      Matthew M. Clark, Teresa A. Rummans, Pamela J. Atherton, Andrea L. Cheville, Mary E. Johnson, Marlene H. Frost, Janis J. Miller, Jeff A. Sloan, Karen M. Graszer, Jean G. Haas, Jean M. Hanson, Yolanda I. Garces, Katherine M. Piderman, Maria I. Lapid, Pamela J. Netzel, Jarrett W. Richardson and Paul D. Brown

      Article first published online: 28 AUG 2012 | DOI: 10.1002/cncr.27776

      In a randomized controlled trial, participation in a 6-session multidisciplinary intervention helped to maintain the quality of life in patients diagnosed with advanced cancer who were receiving radiotherapy. Research should further explore strategies for enhancing the quality of life of patients diagnosed with advanced cancer and their caregivers.

    23. Radiation Oncology
      You have free access to this content
      Single-fraction radiotherapy versus multifraction radiotherapy for palliation of painful vertebral bone metastases—Equivalent efficacy, less toxicity, more convenient : A subset analysis of Radiation Therapy Oncology Group trial 97-14 (pages 888–896)

      David D. Howell, Jennifer L. James, William F. Hartsell, Mohan Suntharalingam, Mitchell Machtay, John H. Suh, William F. Demas, Howard M. Sandler, Lisa A. Kachnic and Lawrence B. Berk

      Article first published online: 16 NOV 2012 | DOI: 10.1002/cncr.27616

      Single-fraction radiation therapy and multifraction radiation therapy for painful vertebral bone metastases result in comparable pain relief and freedom from narcotic use at 3 months in a subset analysis of patients from the randomized, controlled trial Radiation Therapy Oncology Group 97-14.

    24. Symptom Control and Palliative Care
      You have free access to this content
      A score to identify patients with metastatic spinal cord compression who may be candidates for best supportive care (pages 897–903)

      Dirk Rades, Michael Hueppe and Steven E. Schild

      Article first published online: 12 OCT 2012 | DOI: 10.1002/cncr.27849

      In a series of 2029 patients treated with radiotherapy for metastatic spinal cord compression, a scoring system was developed that identifies patients who may be candidates for best supportive care or single-fraction radiotherapy. In patients with a very high probability of dying within 2 months, overtreatment with intensive therapies can be avoided.

    25. Translational Research
      You have free access to this content
      The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas (pages 904–914)

      Vikas Sehdev, Ahmed Katsha, Jeffrey Ecsedy, Alexander Zaika, Abbes Belkhiri and Wael El-Rifai

      Article first published online: 12 SEP 2012 | DOI: 10.1002/cncr.27801

      The combination of alisertib and docetaxel exhibits enhanced anticancer potency in upper gastrointestinal adenocarcinomas both in vitro and in vivo. Therefore, the alisertib and docetaxel combination can mediate a better therapeutic outcome in patients with gastrointestinal cancers.

    26. You have free access to this content
      UBE4B levels are correlated with clinical outcomes in neuroblastoma patients and with altered neuroblastoma cell proliferation and sensitivity to epidermal growth factor receptor inhibitors (pages 915–923)

      Peter E. Zage, Natalie Sirisaengtaksin, Yin Liu, Monica Gireud, Brandon S. Brown, Shana Palla, Kristen N. Richards, Dennis P. M. Hughes and Andrew J. Bean

      Article first published online: 18 SEP 2012 | DOI: 10.1002/cncr.27785

      The authors report an association between UBE4B gene expression and outcomes of patients with neuroblastoma and demonstrate that levels of UBE4B influence neuroblastoma tumor cell proliferation, EGFR degradation, and response to EGFR inhibition. These results suggest that UBE4B-mediated growth factor receptor trafficking may contribute to the poor prognosis of patients who have neuroblastoma with chromosome 1p36 deletions and that UBE4B expression may be a marker that can predict responses of neuroblastoma tumors to treatment.

  3. Errata

    1. Top of page
    2. CancerScope
    3. Original Articles
    4. Errata
    1. You have free access to this content
      Erratum (page 924)

      Article first published online: 28 AUG 2012 | DOI: 10.1002/cncr.27809

      This article corrects:
    2. You have free access to this content
      Erratum (page 924)

      Article first published online: 28 AUG 2012 | DOI: 10.1002/cncr.27810

      This article corrects:

      Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma

      Vol. 112, Issue 5, 1131–1138, Article first published online: 18 JAN 2008

SEARCH

SEARCH BY CITATION